GEMCITABINE

作品数：313被引量：907H指数：11
导出分析报告
相关领域：医药卫生更多>>
相关作者：贾林巴一黄鼎智韩如冰李鸿立更多>>
相关机构：中山大学广州医学院天津医科大学广州市第一人民医院更多>>
相关期刊：更多>>
相关基金：国家自然科学基金中国博士后科学基金广东省社会发展领域科技计划项目国家重点基础研究发展计划更多>>
-
在结果中检索

检索结果分析

结果分析中...
选择条件：
  • 期刊=Cancer Drug Resistancex
共 条 记 录，以下是1-7
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models
《Cancer Drug Resistance》2024年第1期297-308,共12页Aubrey L.Miller Patrick L.Garcia Rebecca B.Vance Eric O.Heard Eric J.Brown Karina J.Yoon 
NIH grant R01CA208272(to Yoon KJ).
Aim:Cell division cycle 25B(CDC25B)belongs to the CDC25 family of phosphatases that regulate cell cycle progression.CDC25B also contributes to tumor initiation and progression,but no connection between CDC25B levels a...
关键词：Cell division cycle 25B(CDC25B) pancreatic ductal adenocarcinoma(PDAC) GEMCITABINE patient-derived xenograft(PDX)models BET inhibitor(BETi) gemcitabine-resistant(gemR)models 
AdipoRon and Pancreatic Ductal Adenocarcinoma:a future perspective in overcoming chemotherapyinduced resistance?被引量：1
《Cancer Drug Resistance》2022年第3期625-636,共12页Luigi Sapio Angela Ragone Annamaria Spina Alessia Salzillo Silvio Naviglio 
The latest scientific knowledge has provided additional insights accountable for the worst prognosis for pancreatic ductal adenocarcinoma(PDAC).Among the causative factors,the aptitude to develop resistance towards ap...
关键词：PDAC AdipoRon GEMCITABINE RESISTANCE 
Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer
《Cancer Drug Resistance》2021年第4期881-884,共4页Fuyuhiko Motoi 
This work was supported in part by JSPS KAKENHI Grant Number 19K09209.
Gemcitabine has been used as a key drug for the treatment of pancreatic ductal adenocarcinoma.Although surgery remains the mainstay for cure of this lethal disease,the effect is quite limited,even for resectable disea...
关键词：GEMCITABINE chemo-resistance pancreatic cancer multi-modal therapy SURGERY 
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance被引量：1
《Cancer Drug Resistance》2021年第4期904-922,共19页Ornella Randazzo Stella M.Cascioferro Camilla Pecoraro Widad Ait Iddouch Amir Avan Barbara Parrino Daniela Carbone Ugo Perricone Godefridus J.Peters Patrizia Diana Elisa Giovannetti 
This work was supported by Cancer Center Amsterdam(CCA)Foundation grants 2015 and 2018;Italian Association for Cancer Research(AIRC)IG grant to Giovannetti E,European Union 2014-2020 PON Ricerca e Innovazione grant from the Italian Ministry of Education,University and Research,entitled“PROGEMA-Processi Green per l’Estrazione di Principi Attivi e la Depurazione di Matrici di Scarto e Non”(ARS01_00432)to Diana P.
Aim:Because mutations of splicing factor 3B subunit-1(SF3B1)have been identified in 4%of pancreatic ductal adenocarcinoma(PDAC)patients,we investigated the activity of new potential inhibitors of SF3B1 in combination ...
关键词：Pancreatic ductal adenocarcinoma GEMCITABINE indole derivatives anti-proliferative activity anti-migratory activity SF3B1 RON hENT1 
Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance被引量：2
《Cancer Drug Resistance》2020年第4期819-831,共13页Yuriko Saiki Shuto Hirota Akira Horii 
Gemcitabine is a cytidine analogue frequently used in the treatment of various cancers.However,the development of chemoresistance limits its effectiveness.Gemcitabine resistance is regulated by various factors,includi...
关键词：GEMCITABINE CHEMORESISTANCE deoxycytidine kinase human equilibrative nucleoside transporter 1 cytidine deaminase ATP-binding cassette transporters METABOLISM 
Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma被引量：3
《Cancer Drug Resistance》2020年第3期572-585,共14页Aubrey L.Miller Patrick L.Garcia Tracy L.Gamblin Rebecca B.Vance Karina J.Yoon 
Aim:Gemcitabine is a frontline agent for locally-advanced and metastatic pancreatic ductal adenocarcinoma(PDAC),but neither gemcitabine alone nor in combination produces durable remissions of this tumor type.We develo...
关键词：Gemcitabine resistance patient-derived xenograft ribonucleotide reductase subunit M1 ribonucleotide reductase subunit M2 human concentrative nucleoside transporter 1 human equilibrative nucleoside transporter 1 cytidine deaminase deoxycytidine kinase 
Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs被引量：1
《Cancer Drug Resistance》2019年第4期994-1001,共8页William H.Gmeiner 
Research reported in this publication was supported by the National Cancer Institute’s Cancer Center Support Grant(P30CA012197)issued to the Wake Forest Baptist Comprehensive Cancer Center.Gmeiner WH is supported by NIH grant(NIH-NCI R21 CA218933).
Topoisomerases are well-validated targets for cancer chemotherapy and DNA topoisomerase 1(Top1)is the sole target of the camptothecin(CPT)class of anticancer drugs.Over the last 20 years,multiple studies have shown To...
关键词：DNA topoisomerase 1 cancer chemotherapy CYTARABINE GEMCITABINE FLUOROPYRIMIDINE 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部